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Background: Health-related quality of life (HRQoL) data in depression are limited. We studied the impact of antidepressant (AD)
treatment onHRQoL outcomes in depressed patients and investigated factors associated with these outcomes in routine practice settings.
Methods: The Factors Influencing Depression Endpoints Research (FINDER) study was a 6-month, European, prospective,
observational study, designed to estimate HRQoL in 3468 adult patients with a clinically diagnosed episode of depression at
baseline and at 3 and 6-months after commencing AD treatment. HRQoL was assessed by the Medical Outcome Short-Form (36)
Health Survey (SF-36) and European Quality of Life-5 Dimensions (EQ-5D). Regression analysis identified baseline and treatment
variables independently and significantly associated with HRQoL outcomes.
Results: Most HRQoL improvement occurred within 3 months of starting treatment. Better HRQoL outcomes were strongly associated
with fewer somatic symptoms at baseline, AD treatment taken and not switching within AD groups. Education and occupational status
were also important. Depression variables (number of previous depressions and current episode duration) were consistently associated
withworseHRQoL outcomes. Self-rated depression severitywas associatedwith poorer outcomes on the SF-36mental component only.
Limitations: As this was an observational study, the important finding that between and within AD group switching impacted
HRQoL will need to be investigated in more controlled settings.⁎ Corresponding author. Eli Lilly and Company Limited, Lilly Research Centre, Erl Wood Manor, Sunninghill Road, Windlesham, Surrey, GU20
6PH, UK. Tel: +44 0 1276 483243; fax: +44 0 1276 483192.
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297C. Reed et al. / Journal of Affective Disorders 113 (2009) 296–302Conclusions: Receiving an AD treatment was associated with large improvements in HRQoL, but switching within AD groups was
consistently associated with poorer outcomes. Somatic symptoms, including painful symptoms, are often present in depressed
patients and appear to negatively impact HRQoL outcomes.
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Health-related quality of life (HRQoL) is impaired in
patients with depression, especially when compared to
the general population and patients with other chronic
diseases, such as diabetes, arthritis or cardiovascular
disease (Hays et al., 1995; Wells et al., 1989, 1999).
There is increasing interest in HRQoL as a measure of
response to antidepressant treatment because it encom-
passes not only symptoms, but also physical, mental and
social functioning as well as role performance (Demyt-
tenaere et al., 2002). Thus, assessment of HRQoL may
provide a more comprehensive evaluation of treatment
response than one based solely on improvement in
emotional symptoms of depression.
Factors Influencing Depression Endpoints Research
(FINDER) was a 6-month, observational study to
assess the HRQoL of outpatients with a depressive
episode in routine primary care and specialist settings
(Bauer et al., 2008; Garcia-Cebrian et al., 2008). The
aims of the present report are to describe the HRQoL
outcomes at three and six months after commencing
pharmacotherapy for depression and to determine
which factors are associated with HRQoL changes
over time.
2. Methods
2.1. Study design and subjects
The design and methods of FINDER have been
reported in detail elsewhere (Bauer et al., 2008; Garcia-
Cebrian et al., 2008). Briefly, primary care physicians
or specialists (mostly psychiatrists) enrolled adult
patients (≥18 years) presenting during the normal
course of care with a clinical diagnosis of depression
who were about to commence antidepressant treatment.
The study was approved in all countries according to
local requirements for ethics and/or regulatory
approvals for observational studies, and all patients
gave written informed consent. Data were collected at
baseline and after 3 and 6 months during routine care
visits.2.2. Data collected
Data recorded at baseline included patient socio-
demographics, psychiatric history, duration of the
current depressive episode and presence of comorbid
chronic medical conditions and functional syndromes.
Antidepressants prescribed were grouped as follows:
selective serotonin reuptake inhibitors (SSRIs), serotonin
noradrenaline reuptake inhibitors (SNRIs), tricyclic and
tetracyclic antidepressants (TCAs), others (including
herbal remedies, lithium, monoamine oxidase inhibitors),
or combinations of antidepressants frommore than one of
these groups.
HRQoL was scored by patients using the 36-item
Short-Form Health Survey (SF-36 version 2.0)
(Ware et al., 1998) and the European Quality of Life-5
Dimensions (EQ-5D) (Brooks, 1996). Anxiety and
depression symptoms were rated by patients using the
Hospital Anxiety and Depression Scale (HADS) (Zig-
mond and Snaith, 1983) giving two subscales; HADS-D
(depression) and HADS-A (anxiety). Somatic symptoms
were assessed by way of the 28-item Somatic Symptom
Inventory (SSI-28) (Barsky et al., 1986), consisting of
seven pain-related items (SSI-pain) and 21 somatic items
(SSI-somatic). Overall pain severity was rated by
patients using a Visual Analogue Scale (VAS, 0–100),
with ratings N30 considered to be moderate/severe pain.
2.3. Statistical analysis
Descriptive statistics were calculated for each vari-
able for all 3468 patients eligible for analysis at baseline,
but only those with at least one follow-up visit were
included in the regression analyses.
2.3.1. Analysis of loss to follow-up
We compared the baseline characteristics and change
scores from baseline to 3 months for the HRQoL
variables for two groups: those with data at 3 months
only; and those with either data at both 3 and 6 months
or at 6 months only. Logistic regression analysis was
performed to identify variables significantly associated
with loss to follow-up using the same set of independent
Fig. 1. Mean (and standard deviation) SF-36 and EQ-5D scores at
baseline, 3 and 6 months. SF-36 MCS and PCS scores were
normalised to a mean of 50 (SD 10) for the general US adult
population. Mean EQ-5D Health State Index (HSI) scores were
converted from a 0–1 scale to a 0–100 scale. MCS, mental component
summary; PCS, physical component summary.
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following exceptions: (1) baseline score for the
dependent variable was not applicable, (2) group of
antidepressant (AD) taken between baseline and
3 months was replaced with the group of AD prescribed
at baseline, and (3) switching variable (switch of AD
treatment taken during the first 3 months and that taken
during the second 3 months) was not used (inclusion
would have excluded any patient without data at all
observations).
2.3.2. Main analysis
Backward regression analysis was performed to
identify variables independently associated with
HRQoL outcomes. Separate models were fitted for
each of the following outcome variables: SF-36 (mental
component summary [MCS], physical component
summary [PCS]), EQ-5D (visual analogue scale
[VAS], health status index [HSI]). A mixed-effects
model repeated measures (MMRM) analysis with
unstructured covariance structure was used. Indepen-
dent variables were removed from the full model until
only statistically significant (p≤ 0.05) variables
remained.
3. Results
3.1. HRQoL scores at baseline and follow-up
The socio-demographic and clinical characteristics of
the FINDER study population are reported elsewhere
(Garcia-Cebrian et al., 2008). The mean unadjusted
scores for SF-36 and EQ-5D at baseline, 3 and 6 months
(Fig. 1) show HRQoL improvements at 3 months, with a
further smaller improvement at 6 months.
3.2. Loss to follow-up analysis
Of the 3468 patients at baseline, 343 (9.9%) had no
follow-up data, 271 (7.8%) had data at 3 months only,
and 2854 (82.3%) had data at both 3 and 6 months or
6 months only.
Three variables were significantly associated with
loss to follow-up: country (pb0.001), younger age at
first depressive episode (p=0.001) and higher SSI-
somatic score at baseline (p=0.019). Severity of
depression (HADS-D) was not significantly asso-
ciated with the likelihood of remaining in the study.
There were no systematic differences in HRQoL
change scores during the first 3 months of treatment in
patients with and without 6 month follow-up (data not
shown).3.3. Factors associated with HRQoL changes over
6 months
The independent variables significantly associated
with HRQoL outcomes are summarised in Table 1. The
estimates given are the change in respective outcome
variable (SF-36 or EQ-5D) associated with an increase
of 1 unit for continuous variables or between specified
levels for categorical variables.
Switching treatment within AD groups was consis-
tently associated with smaller improvements in HRQoL
outcomes compared with no switch in AD group,
whereas switching AD treatment between groups was
either not significantly associated with HRQoL out-
come, or, where significant (SF-36 MCS and EQ-5D
HSI), the effect on HRQoL was consistently smaller
than for switches within groups. For the independent
variable “AD taken between baseline and 3 months”,
both for SF-36 MCS and EQ-5D VAS, the positive
effects compared to no treatment were largest for SSRIs
followed (in decreasing order) by “other” drugs, SNRIs,
TCAs and combinations.
A higher SSI-somatic score at baseline was strongly
and consistently associated with a worse HRQoL
outcome. Higher overall pain VAS at baseline was
significantly associated with worse EQ-5D and there
were weaker associations with poorer SF-36. Socio-
economic factors, such as education and occupational
status, were also consistently associated with HRQoL
(except for education with SF-36 PCS) — patients with
further education had a better HRQoL outcome than
patients with no or mandatory education, and patients
Table 1
Independent variables significantly associated with HRQoL
Independent variable SF-36 MCS (n=2315) SF-36 PCS (n=2140) EQ-5D VAS (n=2224) EQ-5D HSI (n=2230)
Estimate F value P value Estimate F value P value Estimate F value P value Estimate F value P value
Age – – – −0.07 47 b0.001 – – – −0.001 10 0.002
Female (vs. male) 1.08 6 0.016 – – – 1.65 5 0.023 – – –
Further education
(vs. no/mandatory)
1.20 7 0.008 – – – 1.90 6 0.011 0.027 7 0.007
Occupational status
(reference: paid work)
16 b0.001 9 b0.001 18 b0.001 11 b0.001
Other −1.12 −1.09 −3.17 −0.028
Unemployed −3.74 −1.29 −5.83 −0.064
Married/domestic partner
(vs. other)
– – – – – – 1.46 4 0.034 – – –
Number of dependants – – – 0.23 5 0.021 – – – – – –
BMI – – – – – – −0.23 11 b0.001 −0.002 7 0.008
Duration of current episode of
depression (weeks)
−0.05 15 b0.001 −0.02 8 0.005 −0.09 16 b0.001 −0.001 22 b0.001
Number of previous episodes
of depressiona
−0.72 20 b0.001 −0.32 11 0.001 −1.07 17 b0.001 −0.018 29 b0.001
Any other psychiatric illnessa −1.81 16 b0.001 – – – – – – – – –
Any chronic medical condition
(vs. none)
– – – −1.96 48 b0.001 −2.50 12 b0.001 −0.045 21 b0.001
SF-36 MCS scoreb 0.24 71 b0.001 – – – – – – – – –
SF-36 PCS scoreb – – – 0.48 727 b0.001 – – – – – –
EQ-5D VASb – – – – – – 0.30 271 b0.001 – – –
EQ-5D HSIb – – – – – – – – – 0.219 158 b0.001
SSI-somatic −2.10 31 b0.001 −0.91 13 b0.001 −3.34 33 b0.001 −0.051 41 b0.001
HADS-D −0.21 11 0.001 – – – – – – – – –
HADS-A – – – 0.11 9 0.003 – – – – – –
Overall pain VAS −0.02 5 0.026 −0.02 7 0.007 −0.06 17 b0.001 −0.001 35 b0.001
AD taken between baseline
and 3 months (reference:
no treatment)
5 b0.001 – – – 4 0.001 – – –
Combinations 2.78 (ns) 4.61 (ns)
Other drugs 4.73 7.61
SNRI 4.44 7.52
SSRI 5.21 7.68
TCA 3.22 4.99
Switch⁎ (reference: no switch) 19 b0.001 9 b0001 10 b0.001 21 b0.001
Between AD group −1.46 −0.44 (ns) −0.21 (ns) −0.041
Within AD group −5.55 −2.44 −6.78 −0.117
Countryc 3 b0.001 4 b0.001 5 b0.001 4 b0.001
P values b0.05 are reported as statistically significant. Estimates represent the change in the dependent variable associated with a difference of 1 unit
(or 1 category for categorical variables) in the independent variable. Greater F values and smaller P values give an indication of the relative strength
of association of the independent variables with the HRQoL outcome. All independent variables are at baseline unless otherwise specified.
Other independent variables included in the regression analysis but not significant in any of theHRQoLoutcomemodelswere: age at first episode, smoking.
aIn 24 months preceding baseline bOnly included in the relevant HRQoLmodel. cCountry is a known source of variation which was adjusted for in the
current analysis but estimates are not presented.
⁎Switch between what was taken between baseline and 3 months and what was taken between 3 months and 6 months.
SF-36 scores 0–100; higher scores reflect better HRQoL.
EQ-5D VAS scores 0–100 and HSI scores 0–1; higher scores reflect better HRQoL.
AD, antidepressant; BMI, body mass index; EQ-5D, EuroQol 5-dimensions; HSI, health state index; MCS, mental component summary; ns, not
statistically significant; PCS, physical component summary; SF-36, 36-item Short-Form Health Survey SNRI, serotonin noradrenaline reuptake
inhibitor; SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic and tetracyclic antidepressants; VAS, visual analogue scale.
299C. Reed et al. / Journal of Affective Disorders 113 (2009) 296–302who were unemployed had a worse HRQoL outcome
than those working for pay.
Depression variables, such as the number of previous
episodes of depression and the duration of the currentdepressive episode, were consistently associated with
worse HRQoL outcomes. In addition, severity of
depression (HADS-D score) at baseline was signifi-
cantly associated with a worse SF-36 MCS score.
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The results of this large observational study showed
that outpatients with an untreated episode of depression
experienced improvements in HRQoL after starting
antidepressant medication. The majority of this improve-
ment occurred in the first 3 months of follow-up. The SF-
36 summary scores show that the HRQoL impairment at
baseline and the improvements during treatment were
much greater for mental health dimensions than for
physical health. Although the study population did not
reach HRQoL levels comparable to general population
norms, the improvements in HRQoL during treatment
were consistentwith clinical studies (Kroenke et al., 2001;
Miller et al., 1998; Detke et al., 2002; Dunner et al., 2001;
Walker et al., 1995; Peveler et al., 2005).
EQ-5D has not been widely used to assess HRQoL in
depressed patients. A recent longitudinal study (Sobocki
et al., 2007) found reduced HRQoL in Swedish primary
care patients with depression; baseline EQ-5D HSI (0.47)
and VAS (40) scores were similar to those in the FINDER
study (0.44 and 44.8, respectively). Likewise, 6 months'
treatment resulted in comparable HRQoL improvements.
A new finding of this study was that switching anti-
depressant within AD groups was consistently asso-
ciated with a worse HRQoL outcome than not switching
treatment, and that a between-group AD switch was
associated with a worse SF-36 MCS and EQ-5D HSI
compared with no switch. This finding may be a ref-
lection of the harder-to-treat nature of patients requiring
a switch of antidepressant rather than the effectiveness of
switching itself. It is common clinical practice to switch
antidepressant medication for patients who have an in-
sufficient response and/or cannot tolerate their initial
antidepressant. However, there is little information
available to guide physicians on which antidepressant
medication to switch to or the consequences of such
switching. After unsuccessful treatment with an SSRI,
remission rates were similar after switching to another
antidepressant, regardless of the class of antidepressant
used (Rush et al., 2006). Moreover, a recent systematic
review concluded that there is no evidence that a bet-
ween-group switch has advantages over a within-group
switch for response and remission rates (Ruhe et al.,
2006). Our findings suggest that if a treatment switch is
necessary, a switch between antidepressant groups may
be less disadvantageous for HRQoL outcomes than a
within-group switch. However, this needs to be con-
firmed in more controlled settings.
An important finding of this study was that in-
creasing severity of depression at baseline (HADS-D)
was significantly associated with a worse HRQoL out-come for SF-36 MCS only. Baseline results of FINDER
(Garcia-Cebrian et al., 2008) and other studies (Pyne
et al., 1997; Sapin et al., 2004; Saarijarvi et al., 2002;
Trivedi et al., 2006) have found that, in cross-sectional
analysis, quality of life is lower in patients with more
severe depression. Several depression-related factors
(longer duration of the current depressive episode and a
higher number of previous depressive episodes) were
also consistently associated with a poorer HRQoL
outcome.
Although somatic symptoms are often present in
depressed patients and may influence depression out-
comes (Tylee and Gandhi, 2005), few studies have
addressed the impact of somatic symptoms on HRQoL.
We found that greater ‘bother’ due to somatic symptoms
at baseline resulted in poorer HRQoL outcomes during
antidepressant treatment. ‘Bother’ in this context could
be understood as a patient's assessment of the frequency
and severity of the somatic symptoms being evaluated.
In FINDER, a higher overall pain VAS score at
baseline was associated with a poorer HRQoL outcome.
Similarly, Munoz et al. (2005) found that greater severity
of painful somatic symptoms was associated with a
reduced quality of life among Latin American outpatients
with depression. Moreover, in primary care patients,
severity of pain was a strong predictor of a poor treatment
response and poor HRQoL outcome at 3 months after
beginning antidepressant therapy (Bair et al., 2004).
Taken together, this indicates that somatic/painful symp-
toms influence patient quality of life, and that depressed
patients with high levels of somatic/painful symptoms
may be more difficult to treat than other patients.
The FINDER study has several limitations. Firstly,
important findings such as the association between
HRQoL outcomes and between- and within-AD group
switching need to be investigated further in more
controlled settings. Secondly, HRQoL instruments
partly measure concepts that are also contained in
depression instruments. However, SF-36 and EQ-5D
focus more on the impact on activities of daily living,
social interactions and related aspects. Symptom
severity and impact on everyday life are probably
closely correlated, which may explain much of the
parallel improvement in HRQoL and depression
symptoms. Lastly, our observation period was limited
to 6 months during which time patients did not approach
general population values for the SF-36 MCS. We are,
therefore, not able to assess whether the time course to
achieving mental HRQoL scores comparable to the
general population is longer than 6 months or whether,
even after treatment, participants remain impaired in this
respect.
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This study showed that several patient- and treat-
ment-related factors are associated with HRQoL out-
comes of depressive episodes in everyday clinical
practice. Receiving an AD treatment was associated
with large improvements in HRQoL, but switching
within AD groups was consistently associated with
poorer outcomes. Somatic symptoms, including painful
symptoms, are often present in depressed patients and
appear to negatively impact HRQoL outcomes.
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